EpiPen Competitor Swoops Back In After Price-Gouging Controversy

Kaleo will make the product free for those without insurance or families with low-income, but it's setting a high price for insurance companies. Meanwhile, Mylan has not reached a settlement with the Department of Justice over how it classified the EpiPen under Medicaid.

USA Today: EpiPen Competitor Will Be Out In February, Free To 200M People

Five months after the CEO of Mylan faced an irate House panel over price increases for its EpiPen auto injectors, a former competitor will be back next month — at a far higher list price, the company announced Thursday. Kaleo, the maker of the Auvi-Q, says the price paid by consumers with commercial insurance will still be far lower for its reintroduced epinephrine auto injector than any of its brand name or generic competitors. (O'Donnell, 1/19)

Reuters: EpiPen Rival To Be Offered Free To Many But High Price For Insurers

Privately held drugmaker Kaleo on Thursday said it would offer its Auvi-Q emergency allergy auto-injector at no cost to many consumers, but set a list price for the EpiPen rival that will be used as the benchmark cost to insurance companies at a whopping $4,500. (Berkrot, 1/19)

Reuters: U.S. Health Agency Tells Grassley There Is No EpiPen Deal Yet

Mylan NV has yet to reach a settlement with the U.S. Department of Justice over the classification in the Medicaid program of its life-saving EpiPen allergy treatment, according to a letter from a regulatory agency disclosed on Thursday. (Humer and Berkrot, 1/19)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics